ALVOTECH S.A.S
ALVOTECH S.A.S
Share · LU2458332611 · ALVO · A3DK8U (XNMS)
Overview
No Price
16.09.2025 20:00
1 day
-
1 week
-
1 month
-
3 months
-
6 months
-
Year to date
-
1 year
-
2 years
-
3 years
-
4 years
-
5 years
-
10 years
-
20 years
-
Max
-
Current Prices from ALVOTECH S.A.S
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
ALVO
USD
16.09.2025 20:00
7,96 USD
-0,16 USD
-1,97 %
Company Profile for ALVOTECH S.A.S Share
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Company Data

Name ALVOTECH S.A.S
Company Alvotech
Symbol ALVO
Website https://www.alvotech.com
Primary Exchange XNMS Frankfurt
WKN A3DK8U
ISIN LU2458332611
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Robert Wessman
Market Capitalization 3 Mrd.
Country Iceland
Currency EUR
Employees 1,0 T
Address Saemundargata 15-19, 102 Luxembourg
IPO Date 2022-06-16

Ticker Symbols

Name Symbol
Frankfurt Z45.F
NASDAQ ALVO
More Shares
Investors who hold ALVOTECH S.A.S also have the following shares in their portfolio:
DZ BANK      IS.A2873
DZ BANK IS.A2873 Bond
GENF KT. 12-22
GENF KT. 12-22 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025